•Oculgen enrolls first US patient in global phase 2/3 wet AMD trial•Ollin raises $330M to advance OLN324 in phase 3 studies for DME and wet AMD•Study identifies stroke risks following ischemic ocular events•Study suggests ocular history may raise risk for recurrent shingles•Genentech's sBLA for subcutaneous TED therapy receives FDA priority review•Oculgen enrolls first US patient in global phase 2/3 wet AMD trial•Ollin raises $330M to advance OLN324 in phase 3 studies for DME and wet AMD•Study identifies stroke risks following ischemic ocular events•Study suggests ocular history may raise risk for recurrent shingles•Genentech's sBLA for subcutaneous TED therapy receives FDA priority review
HEADLINES
![[object Object]](/_next/image/?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F51cpf7jm%2Fproduction%2Fa59f0611b99f404a5cf253958bf4abff5320346c-1200x628.png%3Fw%3D2400%26q%3D100%26fit%3Dfill%26auto%3Dformat&w=3840&q=75)
FEATURED
Federal agency warns that Lupin’s generic of the prescription-based Pred Forte may have the presence of a foreign substance in its formulation.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
